Ziyi Yang1,2,3, Yizhao Xie4,5, Cheng Liu1,2,3, Xin Liu4,5, Shaoli Song1,2,3, Yingjian Zhang1,2,3, Rui Ge6, Biyun Wang4,5, Zhongyi Yang1,2,3. 1. Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. 2. Center for Biomedical Imaging, Fudan University, Shanghai, China. 3. Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China. 4. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 5. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. 6. Department of General Surgery, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
Abstract
BACKGROUND: For patients with previously diagnosed dual primary tumors, it is usually difficult to determine the diagnosis and treatment of stage IV recurrence. The study was to explore the influences of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT) in the diagnosis of estrogen receptor (ER) positive breast cancer combined with other primary tumor with distant metastases. METHODS: Multidisciplinary team were organized to explore the definite clinical value of 18F-FES PET/CT in stage IV patients suffered from ER-positive breast cancer and another primary tumor synchronously or metachronously. Thirty-two female patients were retrospectively analyzed who underwent 18F-FES PET/CT scans in our center. Before and after reading 18F-FES reports, the team members from department of surgery, oncology and radiotherapy should make decisions of management strategy. RESULTS: Totally, the multidisciplinary team completed the management decision-making of the 32 patients before and after 18F-FES PET/CT scans. 87.5% (n=28) of the patients were considered to benefit from 18F-FES reports for diagnosis and treatment decisions. Out of the 28 patients, 7 patients (7/32, 21.9%) were considered to definitely change the management strategies while 12 patients (12/32, 37.5%) was instructive to develop management plans after the scan. The other 9 patients were suggested reassuring decision-making process by 18F-FES PET/CT. CONCLUSIONS: 18F-FES PET/CT scans have clinical effects on diagnosis and treatment strategies of stage IV patients suffered from ER-positive breast cancer and another primary tumor. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.
BACKGROUND: For patients with previously diagnosed dual primary tumors, it is usually difficult to determine the diagnosis and treatment of stage IV recurrence. The study was to explore the influences of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT) in the diagnosis of estrogen receptor (ER) positive breast cancer combined with other primary tumor with distant metastases. METHODS: Multidisciplinary team were organized to explore the definite clinical value of 18F-FES PET/CT in stage IV patients suffered from ER-positive breast cancer and another primary tumor synchronously or metachronously. Thirty-two female patients were retrospectively analyzed who underwent 18F-FES PET/CT scans in our center. Before and after reading 18F-FES reports, the team members from department of surgery, oncology and radiotherapy should make decisions of management strategy. RESULTS: Totally, the multidisciplinary team completed the management decision-making of the 32 patients before and after 18F-FES PET/CT scans. 87.5% (n=28) of the patients were considered to benefit from 18F-FES reports for diagnosis and treatment decisions. Out of the 28 patients, 7 patients (7/32, 21.9%) were considered to definitely change the management strategies while 12 patients (12/32, 37.5%) was instructive to develop management plans after the scan. The other 9 patients were suggested reassuring decision-making process by 18F-FES PET/CT. CONCLUSIONS: 18F-FES PET/CT scans have clinical effects on diagnosis and treatment strategies of stage IV patients suffered from ER-positive breast cancer and another primary tumor. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Entities:
Keywords:
18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT); double primary cancer; estrogen receptor-positive breast cancer (ER-positive breast cancer); management strategy
Authors: Michel van Kruchten; Elisabeth G de Vries; Andor W Glaudemans; Meta C van Lanschot; Martijn van Faassen; Ido P Kema; Myles Brown; Carolien P Schröder; Erik F de Vries; Geke A Hospers Journal: Cancer Discov Date: 2014-11-07 Impact factor: 39.397
Authors: Nicholas Donin; Christopher Filson; Alexandra Drakaki; Hung-Jui Tan; Alex Castillo; Lorna Kwan; Mark Litwin; Karim Chamie Journal: Cancer Date: 2016-07-05 Impact factor: 6.860
Authors: Jorianne Boers; Clasina M Venema; Erik F J de Vries; Andor W J M Glaudemans; Thomas C Kwee; Ed Schuuring; John W M Martens; Sjoerd G Elias; Geke A P Hospers; Carolina P Schröder Journal: Eur J Cancer Date: 2019-12-28 Impact factor: 9.162
Authors: F Dehdashti; J E Mortimer; B A Siegel; L K Griffeth; T J Bonasera; M J Fusselman; D D Detert; P D Cutler; J A Katzenellenbogen; M J Welch Journal: J Nucl Med Date: 1995-10 Impact factor: 10.057
Authors: Mary L Gemignani; Sujata Patil; Venkatraman E Seshan; Michelle Sampson; John L Humm; Jason S Lewis; Edi Brogi; Steven M Larson; Monica Morrow; Neeta Pandit-Taskar Journal: J Nucl Med Date: 2013-08-22 Impact factor: 10.057